International Journal of Drug Policy
Volume 22, Issue 1 , Pages 34-40 , January 2011

Guidelines for better harm reduction: Evaluating implementation of best practice recommendations for needle and syringe programs (NSPs)

Received 22 December 2009 ,Revised 16 February 2010 ,Accepted 16 March 2010.

References 

  1. Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction. 2007;102(4):638–646
  2. Boyd S, Johnson JL, Moffat B. Opportunities to learn and barriers to change: Crack cocaine use in the Downtown Eastside of Vancouver. Harm Reduction Journal. 2008;5(34):
  3. Burrows D. High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: Case studies (UNAIDS Best Practice Collection). 2006;Retrieved from Joint United Nations Programme on HIV/AIDS (UNAIDS) website: http://data.unaids.org/Publications/IRC-pub07/JC1254-HighCoverageIDU_en.pdf
  4. Buxton JA, Preston EC, Mak S, Harvard S, Barley J, BC Harm Reduction Strategies and Services Committee . More than just needles: An evidence-informed approach to enhancing harm reduction supply distribution in British Columbia. Harm Reduction Journal. 2008;5(37):
  5. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PC, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. Journal of the American Medical Association. 1999;282(15):1458–1465
  6. Caflisch C, Wang J, Zbinden R. The role of syringe filters in harm reduction among injection drug users. American Journal of Public Health. 1999;89(8):1252–1254
  7. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Canadian Medical Association Journal. 1997;157(4):408–416
  8. DeBeck K, Kerr T, Li K, Fischer B, Buxton J, Montaner J, et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Canadian Medical Association Journal. 2009;181(9):585–589
  9. Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: Syringe exchange in the United States. Addiction. 2009;104(9):1441–1446
  10. Dillman DA. Mail and internet surveys: The tailored design method. 2nd ed.. New York: John Wiley; 2000;
  11. Fischer B, Powis J, Cruz MF, Rudzinski K, Rehm J. Hepatitis C virus transmission among oral crack users: Viral detection on crack paraphernalia. European Journal of Gastroenterology and Hepatology. 2008;20(1):29–32
  12. Garden J, Roberts K, Taylor A, Robinson D. Evaluation of the provision of single use citric acid sachets to injecting drug users. Edinburgh: Effective Interventions Unit, Scottish Centre for Infection and Environmental Health; 2003;Retrieved from Drug Misuse Information Scotland website: http://www.drugmisuse.isdscotland.org/eiu/pdfs/citric_acid_full.pdf
  13. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. Bulletin of the World Health Organization. 2004;82(10):724–731
  14. Hankins CA. Syringe exchange in Canada: Good but not enough to stem the HIV tide. Substance Use and Misuse. 1998;33(5):1129–1146
  15. Haydon E, Fischer B. Crack use as a public health problem in Canada. Canadian Journal of Public Health. 2005;9(3):185–188
  16. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18(S1):S133–S138
  17. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. Journal of Acquired Immune Deficiency Syndromes. 2001;28(3):273–278
  18. Leonard, L., DeRubeis, E., Germain, A., Prince, M., Medd, E., & Reynolds, A. (2008 February). Ontario Harm Reduction Distribution Program provincial report outcome evaluation wave one – baseline. Ottawa: HIV Prevention Research Team, Department of Epidemiology and Community Medicine, University of Ottawa. Retrieved from University of Ottawa, Faculty of Medicine website: http://www.medicine.uottawa.ca/epid/assets/documents/PROVINCIAL%20OHRDP%20Wave%201%20Evaluation%20Report%20FINAL(with%20reference).pdf.
  19. Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. “I inject less as I have easier access to pipes”: Injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. International Journal of Drug Policy. 2008;19(3):255–264
  20. Macías J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: Association with sharing the inhalation implements of crack. Liver International. 2008;28(6):781–786
  21. McKnight CA, Des Jarlais DC, Perlis T, Eigo K, Krim M, Ruiz M, et al. Syringe exchange programs—United States, 2005. Morbidity and Mortality Weekly Report. 2007;56(44):1164–1167
  22. McMahon J, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. Journal of Psychoactive Drugs. 2003;35(4):455–460
  23. Millson P, Leonard L, Remis R, Strike C, Challacombe L. Injection drug use, HIV and HCV infection in Ontario: The evidence 1992–2004. Toronto: HIV Social, Behavioural and Epidemiological Studies Unit, Faculty of Medicine, University of Toronto; 2005;Retrieved from Ministry of Health and Long-Term Care website: http://www.health.gov.on.ca/english/providers/pub/aids/reports/injection_druguse_hiv_hcv_infection_ontario_evi.pdf
  24. Ministry of Health and Long-Term Care . Ontario public health standards 2008. 2008;Retrieved from Ministry of Health and Long-Term Care website: http://www.health.gov.on.ca/english/providers/program/pubhealth/oph_standards/ophs/progstds/pdfs/ophs_2008.pdf
  25. Nyamathi AM, Dixon EL, Robbins W, Smith C, Wiley D, Leake B, et al. Risk factors for hepatitis C virus infection among homeless adults. Journal of General Internal Medicine. 2002;17(2):134–143
  26. Ontario Needle Exchange Coordinating Committee. (Producer). (2006). The sleeping giant: A day in the life of a needle exchange program. Available from: http://www.ohtn.on.ca/Videos/sleeping%20giant.wmv.
  27. Paone D, Clark J, Qiuhu S, Purchase D, Des Jarlais DC. Syringe exchange in the United States, 1996: a national profile. American Journal of Public Health. 1999;89(1):43–46
  28. Parsons J, Hickman M, Turnbull PJ, McSweeney T, Stimson GV, Judd A, et al. Over a decade of syringe exchange: Results from 1997 UK survey. Addiction. 2002;97(7):845–850
  29. Porter J, Bonilla L, Drucker E. Methods of smoking crack as a potential risk factor for HIV infection: Crack smokers’ perceptions and behavior. Contemporary Drug Problems. 1997;24(2):319–347
  30. Pratt C-CNU, Paone D, Carter RJ, Layton MC. Hepatitis C screening and management practices: A survey of drug treatment and syringe exchange programs in New York City. American Journal of Public Health. 2002;92(8):1254–1256
  31. Reid R. A benefit–cost analysis of syringe exchange programs. Journal of Health and Social Policy. 2000;11(4):41–57
  32. Remis, R. (2007). Unpublished raw data.
  33. Statistics Canada . Canada at a glance 2009. Ottawa: Minister of Industry; 2009;Retrieved from Statistics Canada website: http://www.statcan.gc.ca/pub/12-581-x/12-581-x2008001-eng.pdf
  34. Strike, C. (2008). Unpublished raw data.
  35. Strike C, Challacombe L, Myers T, Millson M. Needle exchange programs: Delivery and access issues. Canadian Journal of Public Health. 2002;93(5):339–343
  36. Strike C, Leonard L, Millson M, Anstice S, Berkeley N, Medd E. Ontario needle exchange programs: Best practice recommendations. Toronto: Ontario Needle Exchange Coordinating Committee; 2006;
  37. Strike C, Myers T, Millson M. Finding a place for needle exchange programs. Critical Public Health. 2004;14(3):261–275
  38. Strike C, Wenghofer E, Gnam W, Hillier W, Veldhuizen S, Millson M. Physician peer assessments for compliance with methadone maintenance treatment guidelines. Journal of Continuing Education in the Health Professions. 2007;27(4):208–213
  39. Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Substance Use and Misuse. 2004;39(2):211–224
  40. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users: A report. Substance Use and Misuse. 2001;36(4):523–534
  41. World Health Organization . Policy brief: Provision of sterile injecting equipment to reduce HIV transmission. 2004;Retrieved from World Health Organization website: http://www.who.int/hiv/pub/advocacy/en/provisionofsterileen.pdf
  42. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. International Journal of Drug Policy. 2005;16S:S31–S44

PII: S0955-3959(10)00061-7

doi: 10.1016/j.drugpo.2010.03.007

International Journal of Drug Policy
Volume 22, Issue 1 , Pages 34-40 , January 2011

Article Tools